You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Baxter
AstraZeneca
Mallinckrodt
McKinsey

Last Updated: January 21, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Senicapoc

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Senicapoc?

Senicapoc is an investigational drug.

There have been 4 clinical trials for Senicapoc. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2020.

The most common disease conditions in clinical trials are Anemia, Hemolytic, Congenital, Asthma, Exercise-Induced, and Asthma. The leading clinical trial sponsors are Icagen, Aarhus University Hospital, and Aalborg University Hospital.

There are thirteen US patents protecting this investigational drug and one hundred and four international patents.

Recent Clinical Trials for Senicapoc
TitleSponsorPhase
Senicapoc and Dehydrated StomatocytosisQuest DiagnosticsPhase 3
Senicapoc and Dehydrated StomatocytosisBoston Children’s HospitalPhase 3
Senicapoc in COVID-19 Patients With Severe Respiratory InsufficiencyAalborg University HospitalPhase 2

See all Senicapoc clinical trials

Clinical Trial Summary for Senicapoc

Top disease conditions for Senicapoc
Top clinical trial sponsors for Senicapoc

See all Senicapoc clinical trials

US Patents for Senicapoc

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Senicapoc   Start Trial Methods for treating malaria using potassium channel inhibitors THE CHILDREN'S MEDICAL CENTER CORPORATION (Boston, MA)   Start Trial
Senicapoc   Start Trial Methods and compositions for treating conditions associated with an abnormal inflammatory responses First Wave Bio, Inc. (Ann Arbor, MI)   Start Trial
Senicapoc   Start Trial Gardos channel antagonists Icagen, Inc. (Durham, NC)   Start Trial
Senicapoc   Start Trial Imines as ion channel modulators Icagen, Inc. (Durham, NC)   Start Trial
Senicapoc   Start Trial Method to treat sickle cell disease University of Virginia Patent Foundation (Charlottesville, VA)   Start Trial
Senicapoc   Start Trial Carbonylamino derivatives useful for the treatment of certain inflammatory disorders Aniona Aps (Farum, DK)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Senicapoc

Drugname Country Document Number Estimated Expiration Related US Patent
Senicapoc World Intellectual Property Organization (WIPO) WO2016134353 2035-02-20   Start Trial
Senicapoc Australia AU2016315852 2035-09-01   Start Trial
Senicapoc Canada CA2997136 2035-09-01   Start Trial
Senicapoc Chile CL2018000559 2035-09-01   Start Trial
Senicapoc China CN109562137 2035-09-01   Start Trial
Senicapoc Colombia CO2018003465 2035-09-01   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Baxter
AstraZeneca
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.